A detailed history of Lindbrook Capital, LLC transactions in Xencor Inc stock. As of the latest transaction made, Lindbrook Capital, LLC holds 235 shares of XNCR stock, worth $5,421. This represents 0.0% of its overall portfolio holdings.

Number of Shares
235
Previous 567 58.55%
Holding current value
$5,421
Previous $10,000 60.0%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$15.7 - $21.65 $5,212 - $7,187
-332 Reduced 58.55%
235 $4,000
Q2 2024

Jul 31, 2024

SELL
$18.21 - $24.5 $491 - $661
-27 Reduced 4.55%
567 $10,000
Q4 2023

Jan 31, 2024

BUY
$16.53 - $21.42 $9,108 - $11,802
551 Added 1281.4%
594 $12,000
Q3 2023

Oct 25, 2023

SELL
$20.08 - $25.39 $1,184 - $1,498
-59 Reduced 57.84%
43 $0
Q2 2023

Jul 28, 2023

BUY
$24.77 - $29.9 $1,857 - $2,242
75 Added 277.78%
102 $2,000
Q4 2022

Jan 24, 2023

SELL
$24.79 - $30.86 $5,081 - $6,326
-205 Reduced 88.36%
27 $0
Q3 2022

Nov 10, 2022

BUY
$24.62 - $32.44 $4,825 - $6,358
196 Added 544.44%
232 $6,000
Q2 2022

Aug 01, 2022

BUY
$19.74 - $29.01 $118 - $174
6 Added 20.0%
36 $1,000
Q1 2022

Apr 21, 2022

BUY
$26.68 - $41.63 $800 - $1,248
30 New
30 $1,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.38B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.